Rare insulin-resistance syndrome

Rare insulin-resistance syndromes encompass a heterogeneous group of uncommon genetic disorders characterized by severe resistance to the action of insulin, leading to impaired glucose metabolism despite elevated circulating insulin levels. These conditions affect multiple body systems, most prominently the endocrine and metabolic systems, but also the skin, reproductive system, and musculoskeletal system. This Orphanet grouping (ORPHA:181368) serves as a classification category that includes several distinct clinical entities such as type A insulin resistance syndrome, type B insulin resistance syndrome (autoimmune), Rabson-Mendenhall syndrome, Donohue syndrome (leprechaunism), lipodystrophic syndromes, and other conditions featuring profound insulin resistance as a central feature. Key clinical features shared across these syndromes include severe hyperinsulinemia, impaired glucose tolerance or overt diabetes mellitus, acanthosis nigricans (darkened, thickened skin patches particularly in body folds), and in females, hyperandrogenism manifesting as hirsutism, acne, and polycystic ovary-like features with menstrual irregularities. Depending on the specific syndrome, patients may also exhibit growth abnormalities, dysmorphic features, lipodystrophy (abnormal distribution or loss of body fat), and hepatic steatosis. The severity ranges widely — from relatively mild metabolic disturbances in type A insulin resistance to life-threatening metabolic derangements in Donohue syndrome, which typically presents in the neonatal period. The underlying causes vary by specific syndrome and include mutations in the insulin receptor gene (INSR), autoantibodies against the insulin receptor, or defects in downstream insulin signaling pathways and adipocyte biology. Treatment is challenging and largely supportive, focusing on glycemic control, which is often difficult to achieve with conventional insulin therapy due to the profound resistance. Metformin, thiazolidinediones, and recombinant human IGF-1 (mecasermin) have been used in some forms. Recombinant leptin (metreleptin) has been approved for generalized lipodystrophy-associated insulin resistance. Management typically requires a multidisciplinary approach involving endocrinologists, dermatologists, and reproductive specialists.

Common questions about Rare insulin-resistance syndrome